abstract: UNASSIGNED: Development of novel imaging probes for @entity5 diagnostics remains critical for early detection of disease, yet most imaging agents are hindered by high off-target accumulation (e.g. liver, spleen) and suboptimal @entity5 accumulation. To overcome these limitations, researchers have adapted antibodies for imaging purposes. As @entity5 express atypical patterns of cell surface proteins in comparison to non-cancerous tissues, novel antibody-based imaging agents can be constructed to target individual @entity5 cells or surrounding vasculature. Using molecular imaging techniques, these agents may be utilized for detection of @entity5 and monitoring of therapeutic response. Currently, there are several imaging modalities commonly employed for molecular imaging. These imaging modalities include positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance (MR) imaging, optical imaging (fluorescence and bioluminescence), and photoacoustic (PA) imaging. While antibody-based imaging agents may be employed for a broad range of diseases, this review focuses on the molecular imaging of @entity788 , as there are limited resources for imaging and treatment of @entity9451 . Additionally, @entity788 remains the most lethal @entity5 with an overall 5-year survival rate of approximately 7%, despite significant advances in the imaging and treatment of many other @entity5 . In this review, we discuss recent advances in molecular imaging of @entity788 using antibody-based imaging agents. This task is accomplished by summarizing the current progress in each type of molecular imaging modality described above. Also, several considerations for designing and synthesizing novel antibody-based imaging agents are discussed. Lastly, the future directions of antibody-based imaging agents are discussed, emphasizing the potential applications for personalized medicine.

title: Molecular Imaging of XXXX with Antibodies.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer', 'cancerous malignancies', 'malignancies']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity9451 :: ('MESH:D010195', 'Disease') :: ['pancreatic malignancies']

answer: @entity788 :: (MESH:D010190,Disease) :: ['Pancreatic Cancer']


abstract: OBJECTIVE: To investigate the effect of transcutaneous electrical nerve stimulation (TENS) on acupuncture points and neck exercise in @entity4048 @entity1 . DESIGN: A randomized clinical trial. SETTING: Hospital-based practice. SUBJECTS: Two hundred and eighteen @entity1 with @entity4048 . INTERVENTIONS: Subjects were randomized into three groups, receiving either (1) TENS over the acupuncture points plus infrared irradiation (TENS group); (2) exercise training plus infrared irradiation (exercise group); or (3) infrared irradiation alone (control); twice a week for six weeks. OUTCOME MEASURES: The values of verbal numeric @entity158 scale, Northwick Park Neck Pain Questionnaire, and isometric neck muscle strength were assessed before, at the end of the six-week treatment, and at the six-month follow-up. RESULTS: Results demonstrated that after the six-week treatment, significant improvement in the verbal numerical @entity158 scale was found only in the TENS group (0.60+/-2.54, p = 0.027) and the exercise group (1.57+/-2.67, p < 0.001). Though significant reduction in Northwick Park Neck Pain Questionnaire score was found in all three groups, post-hoc tests showed that both the TENS and the exercise group produced better improvement (0.38+/-0.60% and 0.39+/-0.62% respectively) than the control group (0.23+/-0.63%). Significant improvement (p = < 0.001 to 0.03) in neck muscle strength was observed in all three groups, however, the improvement in the control group was not clinically significant and it could not be maintained at the six-month follow-up. CONCLUSIONS: After the six-week treatment, @entity1 in the TENS and exercise group had a better and clinically relevant improvement in disability, isometric neck muscle strength, and @entity158 . All the improvements in the intervention groups were maintained at the six-month follow-up.

title: A randomized clinical trial of TENS and exercise for @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4048 :: ('MESH:D019547', 'Disease') :: ['chronic neck pain']

answer: @entity4048 :: (MESH:D019547,Disease) :: ['chronic neck pain']


abstract: @entity242 are @entity5 accounting for a high percentage of @entity5 morbidity and mortality in @entity1 and young adults. Surgery and radiation therapy are the accepted treatments for most @entity242 ; however, @entity1 with @entity3 are treated with systemic chemotherapy. Many @entity5 display marginal levels of chemoresponsiveness and new treatment approaches are needed. Deregulation of the G1 checkpoint is crucial for various oncogenic transformation processes, suggesting that many @entity5 cell types depend on @entity20405 activity. Thus, @entity20405 activity appears to represent a promising therapeutic target for @entity5 treatment. In the present work, we explore the efficacy of @entity8985 inhibition using palbociclib ( @entity20406 ), a highly selective inhibitor of @entity20405 , in a panel of @entity242 cell lines and @entity5 xenografts (PDXs). Palbociclib induces senescence in these cell lines and the responsiveness of these cell lines correlated with their levels of @entity8985 mRNA. @entity20406 is also active in vivo against @entity242 displaying high levels of @entity8985 but not against @entity242 displaying low levels of @entity8985 and high levels of @entity986 . The analysis of @entity5 growing after @entity20406 showed a clear decrease in the @entity8985 levels, indicating that clonal selection occurred in these treated @entity5 . In summary, our data support the efficacy of @entity8985 inhibitors against @entity242 displaying increased @entity8985 levels, particularly @entity1492 and @entity808 . Our results also suggest that high levels of @entity986 may indicate poor efficacy of @entity8985 inhibitors.

title: Efficacy of @entity8985 inhibition against @entity242 depends on their levels of @entity8985 and XXXX mRNA.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas', 'Sarcomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'sarcoma tumor', 'malignant tumors', 'cancer']

entities_list: @entity1492 :: ('MESH:D005354', 'Disease') :: ['fibrosarcomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity20406 :: ('MESH:C500026', 'Chemical') :: ['Palbociclib', 'PD0332991', 'palbociclib']

answer: @entity986 :: (1029,Gene) :: ['p16ink4']


abstract: OBJECTIVE: We sought to explore whether @entity390 and @entity391 are predictive of entrapment. Study design and setting We retrospectively evaluated the data regarding orbital floor @entity174 in @entity1 younger than 19-years-old presenting at a tertiary care center from 1990 to 2001. Zygomatic, naso-orbital ethmoid, and displaced orbital rim @entity174 were excluded from our analysis. Data on the @entity174 type, signs and symptoms, ocular motility, surgical repair, and resolution of @entity892 were also collected. RESULTS: Twenty-nine orbital floor @entity174 were identified. One fourth of the @entity1 had @entity390 / @entity391 , and half had trapdoor @entity174 . Seventeen percent of @entity1 had entrapment of the inferior rectus. The positive predictive @entity1209 with a trapdoor @entity174 for entrapment was 83.3% (P = 0.002, Fisher exact test). Half the @entity1 required surgical intervention, most commonly for @entity892 or gaze restriction. Gaze impairment did not resolve in 2 @entity1 . CONCLUSION: @entity1 with trapdoor @entity174 who present with @entity390 / @entity391 are at a high risk of inferior rectus entrapment and poor outcome.

title: Pediatric orbital floor fractures: XXXX / @entity391 as signs of entrapment.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['value of nausea/vomiting']

answer: @entity390 :: (MESH:D009325,Disease) :: ['nausea']


abstract: Walking is generated by the interaction between neural rhythmic and physical activities. In fact, @entity191 ( @entity191 ), which is an example of disease, causes not only @entity2167 but also @entity717 . However, the relationship between @entity2167 and @entity717 has not been determined. The aim of this study was to identify the mechanism of gait rhythm generation. In former research, @entity2167 in @entity191 @entity1 ' walking were characterized by stride intervals, which are more variable and fluctuate randomly. The variability and fluctuation property were quantified using the coefficient of variation (CV) and scaling exponent a. Conversely, because walking is a dynamic process, @entity74 ( @entity74 ) is considered the best way to estimate @entity717 in walking. Therefore, we classified the severity of @entity74 using CV and a. Specifically, @entity191 @entity1 and healthy elderly were classified into three groups: no- @entity74 , mild- @entity74 , and obvious- @entity74 . We compared the contributions of CV and a to the accuracy of this classification. In this study, 45 @entity191 @entity1 and 17 healthy elderly @entity1 walked 200 m. The severity of @entity74 was determined using the modified Hoehn-Yahr scale (mH-Y). @entity1 with mH-Y scores of 2.5 and 3 had mild- @entity74 and obvious- @entity74 , respectively. As a result, CV differentiated no- @entity74 from @entity74 , indicating the correlation between CV and @entity74 . Considering that @entity74 is independent of neural rhythm generation, this result suggests the existence of feedback process from physical activities to neural rhythmic activities. Moreover, a differentiated obvious- @entity74 from mild- @entity74 . Considering a reflects the intensity of interaction between factors, this result suggests the change of the interaction. Therefore, the interaction between neural rhythmic and physical activities is thought to plays an important role for gait rhythm generation. These characteristics have potential to evaluate the symptoms of @entity191 .

title: Relationship between @entity2167 and @entity717 in XXXX @entity1 ' walking.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'People']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['neural rhythm generation disorders']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['postural reflex disorder', 'PRD']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['physical disabilities']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: Localization of @entity4890 to the pineal region is rare. The 7-year-old @entity1 now reported presented with an 18-month history of progressive @entity2055 . CT and MRI scans demonstrated a 2.5x2.5 cm cyst at the pineal region with obstructive @entity1276 . At surgery via an occipital transtentorial approach, a @entity5 " was encountered, and complete resection was achieved. We present the management of this @entity1 with pineal region epidermoid cyst and review 11 cases reported in the literature since 1968. In all, 8 of the 12 @entity1 were males. The age at the time of diagnosis ranged from 7 years to 69 years. @entity1319 and @entity1276 are the most common presenting findings. All but 1 @entity1 underwent direct surgical resection; 1 had stereotactic decompression. Surgical treatment brought about complete resolution of the presenting symptoms and signs in 10 of the 12 cases. One @entity1 had persistent upgaze palsy. One @entity1 died from progression of the pineal region mass. This @entity1 presented with @entity1269 , which is a marker of clinical @entity146 . The authors advocate direct surgical attack as opposed to stereotactic diagnosis and aspiration to: (1) obtain maximal resection and thereby limit the potential for recurrence and delayed complications of the cyst; (2) possibly avoid shunt placement in @entity1 who present with @entity1276 ; and (3) decrease the likelihood of sampling error.

title: XXXX of the pineal region.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'boy', 'child']

entities_list: @entity4890 :: ('MESH:D004814', 'Disease') :: ['epidermoid cysts']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['characteristic "pearly tumour']

entities_list: @entity1269 :: ('MESH:D010291', 'Disease') :: ['hemiparesis']

entities_list: @entity1319 :: ('MESH:D015835', 'Disease') :: ["Parinaud's syndrome"]

answer: @entity4890 :: (MESH:D004814,Disease) :: ['Epidermoid cysts']


abstract: BACKGROUND: @entity1 U three protein 14a ( @entity69170 ) promotes @entity876 degradation. Moreover, @entity69170 expression is upregulated in several types of @entity5 . However, the expression pattern of @entity69170 in @entity157 ( @entity157 ) remains unknown. The aim of this study was to investigate @entity69170 expression and its prognostic value in @entity157 . METHODS: The @entity69170 expression was evaluated using immunohistochemistry (IHC) in @entity157 tissue specimens. The correlations between @entity69170 expression and clinicopathological variables were analyzed. The Kaplan-Meier method was used to analyze the association between @entity69170 expression and survival. Independent prognostic factors associated with @entity1349 ( @entity1349 ) and disease-free survival (DFS) were analyzed using the Cox proportional-hazards regression model. RESULTS: The IHC data revealed that the @entity69170 positivity rate in @entity157 tissue specimens was significantly higher than that in nontumorous tissue specimens (89.9% vs. 72.7%, P < 0.05). The @entity69170 expression was detected in both the nucleolus and the cytoplasm. The positivity rate of nucleolar @entity69170 expression in @entity157 tissue specimens was higher than that in the nontumorous tissue specimens (29.3% vs. 10.1%, P < 0.05). No significant difference was found between @entity157 and nontumorous tissue specimens of cytoplasmic @entity69170 expression (60.6% vs. 62.6%, P > 0.05). In addition, no significant correlation was found between nucleolar @entity69170 expression and other clinicopathological variables. The 5-year @entity1349 and DFS rates in @entity1 with positive nucleolar @entity69170 expression were significantly lower than those in @entity1 with negative @entity69170 expression (P = 0.004 for @entity1349 , P = 0.003 for DFS). Multivariate analysis showed that nucleolar @entity69170 expression was an independent prognostic factor for @entity1349 (P = 0.004) and DFS (P < 0.001). CONCLUSIONS: The positivity rate of @entity69170 expression was significantly higher in @entity157 specimens. Positive expression of nucleolar @entity69170 might act as a novel prognostic predictor for @entity1 with @entity157 .

title: @entity1 U Three Protein 14a Expression is Increased in XXXX and Associated with Poor Prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Human']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity157 :: (MESH:D006528,Disease) :: ['Hepatocellular Carcinoma']


abstract: The case records of 23 @entity1 with classic @entity15607 ( @entity15607 ), or @entity15607 , seen at the National Skin Centre in Singapore, from 1990 to 2001 were reviewed. All @entity1 had clinical and histopathological findings consistent with @entity15607 . There were eight @entity1 and 15 @entity1 (ratio 1:1.6). The mean age at presentation was 35 years. There was a marked predilection for Chinese @entity1 (87%), with a racial distribution of 20:2:1 of Chinese, Malay and Indian @entity1 , respectively. The most frequent site of occurrence was the face, particularly over both cheeks. The majority of @entity1 (90%) treated with oral @entity3352 had a good response within 2-4 weeks. Relapses were frequent in 82.6% of @entity1 and maintenance with @entity3352 or @entity7988 was beneficial. @entity15607 is a rare but important disease entity presenting with recurrent indurated erythematous papulopustules and plaques on the face. Increased awareness of this condition is important as it can mimic many other conditions presenting as red plaques on the face.

title: XXXX ( @entity15607 ) in Singapore: a review of 23 adult cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

entities_list: @entity15607 :: ('MESH:C535953', 'Disease') :: ['Eosinophilic pustular folliculitis', 'eosinophilic pustular folliculitis', "Ofuji's disease", 'EPF']

entities_list: @entity7988 :: ('MESH:D007660', 'Chemical') :: ['ketoprofen']

answer: @entity15607 :: (MESH:C535953,Disease) :: ['Eosinophilic pustular folliculitis']


abstract: The possible association of increased @entity1002 ( @entity1002 ) in @entity1 with increased serum @entity141 was observed in our clinic. Six @entity1 with confirmed @entity459 and hypercalcaemia were studied prospectively. Tc-99m sestamibi gated SPECT was done pre- and postoperatively. The @entity1002 was abnormally high in all the @entity1 pre-operatively, i.e. above the normal reference range (47-61%) as used in our clinic. It decreased in all of them postoperatively, yet in only three @entity1 to values within the normal range. This was associated with normalisation of the serum @entity141 values. The median of the pre-operative @entity1002 was 74% and postoperative it was 61.5%. The median difference was 9% with a 95% CI for the median difference for paired data (6; 26). This was statistically significant. Increased @entity1002 was not previously described as part of the clinical picture of @entity459 . The in vivo effect of chronic hypercalcaemia on LV pump function my need to be revisited.

title: Enhanced myocardial contractility associated with hypercalcaemia of hyperparathyroidism - a case study in six XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity459 :: ('MESH:D049950', 'Disease') :: ['primary hyperparathyroidism']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular ejection fraction', 'LVEF']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: We evaluated therapeutic microcoil embolization in a group of @entity1 with severe @entity548 . MATERIALS AND METHODS: Twenty-seven @entity1 with severe @entity694 due to @entity66 (n = 19), @entity2817 (n = 6), cecal @entity1066 (n = 1), or unknown cause (n = 1) underwent attempted microcoil embolization (n = 25). Microcatheters were used in all procedures, and embolization was performed at the level of the vasa recta or the marginal artery of Drummond. Branches of the superior mesenteric artery were embolized in 12 @entity1 , branches of the inferior mesenteric artery were embolized in 12 @entity1 , and branches of both the superior and inferior mesenteric arteries were embolized in one @entity1 . RESULTS: Technical success was achieved in 93% (25/27) of the procedures. However, immediate hemostasis occurred in 96% (26/27) of @entity1 because in one failed procedure, an occlusive dissection of the inferior mesenteric artery arrested bleeding. Three @entity1 rebled within 24 hr. One @entity1 was treated with endoscopic cauterization, and two @entity1 underwent right hemicolectomy. One @entity1 who underwent right hemicolectomy for rebleeding had ischemic changes found on pathologic analysis of the resected specimen, and a second @entity1 who underwent embolization of branches of the superior and inferior mesenteric arteries developed @entity1188 requiring left hemicolectomy. Prolonged clinical success occurred in 81% (22/27) of @entity1 . CONCLUSION: Therapeutic microcoil embolization for severe @entity548 is an effective and well-tolerated procedure.

title: Superselective microcoil embolization of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['diverticular disease']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['colonic hemorrhage']

entities_list: @entity2817 :: ('MESH:D016888', 'Disease') :: ['angiodysplasia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['bowel infarction']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic bleeding']

answer: @entity548 :: (MESH:D006470,Disease) :: ['colonic hemorrhage']


abstract: OBJECT: The goal of this study was to investigate outcomes in @entity1 with @entity5513 ( @entity5513 ) who were treated with fractionated stereotactic radiotherapy (SRT). METHODS: One hundred one @entity1 with @entity5513 were treated with fractionated SRT at a radiation level of 40 to 50 Gy administered in 20 to 25 fractions over a 5- to 6-week period. The median @entity5 size in these @entity1 was 19 mm (range 3-40 mm), and 27 @entity5 were larger than 25 mm. @entity1 were consistently followed up using magnetic resonance imaging every 6 months for 5 years in principle. The median follow-up period was 45 months. The actuarial 5-year rate of @entity5 control (no growth > 2 mm and no requirement for salvage surgery) was 91.4% (95% confidence interval 85.2-97.6%). Three @entity1 with progressive @entity5 underwent salvage @entity5 resection. The actuarial 5-year rate of useful hearing preservation (Gardner-Robertson Class I or II) was 71%. The observed complications of fractionated SRT included transient @entity2103 (4% of @entity1 ), trigeminal @entity16 (14% of @entity1 ), and balance disturbance (17% of @entity1 ). No new permanent @entity425 occurred after fractionated SRT. Eleven @entity1 (11%) who had progressive communicating @entity1276 ( @entity8884 ) and no evidence of @entity5 growth after fractionated SRT required a shunt. The symptoms of this type of @entity1276 were similar to those of normal-pressure @entity1276 and occurred 4 to 20 months (median 12 months) after fractionated SRT. The mean size (+/- standard deviation) of @entity5 causing symptomatic @entity1276 (25.5 +/- 7.8 mm) was significantly larger than that of other @entity5 (18.2 +/- 8.7 mm) (p = 0.011). Only four of the 72 @entity1 with @entity5 smaller than 25 mm in maximum diameter received a shunt. CONCLUSIONS: Fractionated SRT resulted in an excellent @entity5 control rate, even for relatively large @entity5 , and produced a high rate of hearing preservation that was comparable to the best results of single-fraction radiosurgery. The progression of communicating @entity1276 should be monitored closely, particularly in @entity1 harboring a large @entity5513 .

title: Management of @entity5513 by fractionated stereotactic radiotherapy and associated XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5513 :: ('MESH:D009464', 'Disease') :: ['VS', 'vestibular schwannoma']

entities_list: @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus']

entities_list: @entity8884 :: ('MESH:D008286', 'Disease') :: ['cerebrospinal fluid malabsorption']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve palsy']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['facial weakness']

answer: @entity8884 :: (MESH:D008286,Disease) :: ['cerebrospinal fluid malabsorption']


abstract: The perivascular epithelioid cell has been proposed to be the unifying proliferating cell type in a number of lesions such as @entity359 , @entity3008 , @entity1358 . With the exception of rare examples of @entity359 , they are non-metastasizing. We report four examples of a new member of this family of @entity1824 that occur in abdominopelvic location and show metastatic properties. The @entity1 , all @entity1 , were aged 19 to 41 years (mean, 32), and presented with a @entity5 mass involving the serosa of the ileum, uterus or pelvic cavity. Morphologically, the @entity5 were composed of sheets of large polygonal cells with glycogen-rich clear or eosinophilic cytoplasm and moderately pleomorphic nuclei, traversed by a delicate vasculature, mimicking @entity1358 . There were areas of coagulative @entity39 and occasional mitotic figures. Intracytoplasmic brown pigment was present in two cases. Spindly cells, smooth muscle and fat were absent. @entity3 was present in all, lymph node @entity3 was documented in two and @entity3 to the ovary was present in one case. Two @entity1 developed widespread metastatic disease after 10 and 28 months from diagnosis. One @entity1 showed the clinical signs of @entity2916 . In spite of the epithelial-like appearance, the @entity5 cells were negative for epithelial markers but were strongly positive with the melanogenesis-related marker HMB45. Another melanogenesis marker ( @entity3059 ) was positive in two cases. Other markers including S-100 protein, @entity2277 , @entity2283 and @entity3507 were negative. Thus, these @entity5 are not readily classifiable in the existing schema of known entities, and show overlapping morpho-phenotypic features of clear cell "sugar" @entity2 . We consider them as @entity242 composed of a pure population of uncommitted perivascular epithelioid cell, that lack modulation toward smooth muscle or adipose cells.

title: @entity242 of perivascular epithelioid cells. Report of four cases in young @entity1 , one with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity2283 :: ('1674', 'Gene') :: ['muscle-specific actin, desmin']

entities_list: @entity1824 :: ('MESH:D054973', 'Disease') :: ['perivascular epithelioid cell neoplasms']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['tumor of the lung and epithelioid angiomyolipoma']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['clear cell "sugar" tumor and renal capsuloma', 'clear cell carcinoma']

entities_list: @entity2916 :: ('MESH:D014402', 'Disease') :: ['tuberous sclerosis']

entities_list: @entity3008 :: ('MESH:D018192', 'Disease') :: ['lymphangiomyomatosis']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'Lymphovascular invasion']

entities_list: @entity359 :: ('MESH:D018207', 'Disease') :: ['angiomyolipoma']

answer: @entity2916 :: (MESH:D014402,Disease) :: ['tuberous sclerosis']


abstract: BACKGROUND: Recent clinical trials using @entity2467 + @entity1 cardiac stem cells (CSCs) demonstrated promising results in increasing cardiac function and improving quality of life. However, CSC efficiency is low, likely due to limited cell survival and engraftment after transplantation. The Rho-associated protein kinase (ROCK) inhibitor, @entity12223 , significantly increased cell survival rate, adhesion, and migration in numerous types of cells, including stem cells, suggesting a common feature of the ROCK-mediated apoptotic pathway that may also exist in @entity1 CSCs. In this study, we examine the hypothesis that pretreatment of @entity1 CSCs with @entity12223 protects cells from @entity632 ( @entity3105 ) induced apoptosis. METHODS AND RESULTS: @entity2467 + CSCs were cultured in CSC medium for 3-5 days followed by 48hr treatment with 0 to 10 M @entity12223 alone, 0 to 1.0 M @entity3105 alone, or @entity12223 followed by @entity3105 (48hrs). Cell viability, @entity137 , proliferation, morphology, migration, @entity522 activity, expression levels of apoptotic-related key proteins and @entity2467 + were examined. Results showed that 48hr treatment with @entity12223 alone did not result in great changes in @entity2467 + expression, proliferation, @entity522 activity, or apoptosis; however cell viability was significantly increased and cell migration was promoted. These effects likely involve the ROCK/Actin pathways. In contrast, 48hr treatment with @entity3105 alone dramatically increased @entity522 activity, resulting in cell death. Although @entity12223 alone did not affect the expression levels of apoptotic-related key factors (p- @entity584 , @entity584 , @entity588 , @entity1836 , @entity589 , cleaved @entity522 , and @entity522 ) under basal conditions, it significantly inhibited the @entity3105 -induced increase in cleaved @entity522 and reduced cell death under @entity3105 treatment. CONCLUSIONS: We conclude that preconditioning @entity1 CSCs with @entity12223 significantly reduces @entity3105 -induced cell death and possibly involves the cleaved @entity522 and ROCK/Actin pathways. The beneficial effects of @entity12223 may be applied to stem cell-based therapy to increase cell survival rates after transplantation or to act as a cardiac protective agent for @entity3105 -treated @entity5 @entity1 .

title: Rho-Associated Kinase Inhibitor ( @entity12223 ) Attenuates XXXX -Induced Apoptosis of @entity1 Cardiac Stem Cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['Doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

answer: @entity632 :: (MESH:D004317,Chemical) :: ['Doxorubicin']


abstract: OBJECTIVE: To evaluate the therapeutic potential of @entity4020 ( @entity4020 ) in @entity571 ( @entity571 ) and @entity309 ( @entity309 ) by examining regulation of cytokine antagonist expression. METHODS: Expression of @entity1193 ( @entity1193 ) and soluble @entity5 necrosis factor receptor (sTNFR) was examined by ELISA in cells from freshly isolated synovial fluids (SF) and synovial tissues (ST) from @entity1 with @entity571 or @entity309 , either left untreated or treated with @entity4020 . Single (7) and paired (5) SF and ST cells from @entity571 and @entity309 @entity1 were examined. As well, the ability of @entity4020 to regulate gene expression levels for @entity2159 ( @entity2159 ) and @entity5298 ( @entity5298 ) was examined in freshly isolated SF cells from @entity1 with @entity309 , by reverse transcriptase polymerase chain reaction. RESULTS: @entity1193 and sTNFR were found to be constitutively expressed in @entity571 and @entity309 SF and ST cells. @entity4020 treatment resulted in an increase in both @entity1193 and sTNFR production. Freshly isolated @entity309 SF cells exhibited constitutive @entity5298 gene expression in both the @entity784 and T cell fractions of the SF. In contrast, @entity2159 gene expression levels were undetectable or low. @entity4020 treatment of @entity309 SF cells resulted in upregulation of @entity2159 gene expression in the T cell fraction of the @entity309 SF cells, whereas @entity5298 gene expression remained unaffected. CONCLUSION: These in vitro data suggest a therapeutic role for @entity4020 in the treatment of @entity625 through upregulation of critical cytokine antagonists.

title: Therapeutic implications for interferon-alpha in XXXX : a pilot study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'OA']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity1193 :: ('3557', 'Gene') :: ['IL 1Ra', 'interleukin 1 receptor antagonist', 'IL-1Ra']

entities_list: @entity5298 :: ('8600', 'Gene') :: ['osteoprotegerin ligand', 'OPGL']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

entities_list: @entity2159 :: ('4982', 'Gene') :: ['osteoprotegerin', 'OPG']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: @entity405 + @entity784 presenting in the skin are rare. We describe the clinical and histological features of 18 @entity1 with @entity405 + cutaneous @entity5 , which have been divided into four groups. Seven @entity1 had precedent long histories of rashes, which progressively spread in a presentation similar to that of @entity404 + @entity4888 ( @entity4888 ). Three @entity1 had long-standing localized plaques consistent with a @entity33835 ( @entity33835 ) pattern. Two @entity1 presented with @entity5658 and had peripheral blood involvement consistent with a @entity14041 ( @entity14041 ) pattern and had rapidly progressive clinical courses. Six @entity1 presented with cutaneous nodules of varying sizes and had variable outcomes, with two having rapidly progressive disease, two with indolent recurrences and a further two with complete responses to treatment. Histologically, 12 of the 18 cases showed an @entity5 infiltrate that was most marked in the three @entity33835 cases. @entity2617 was seen in 11 cases. Similar to @entity404 + @entity4888 , the skin-homing antigen, (cutaneous lymphocyte antigen: @entity4619 ), was strongly expressed in 13 of 16 tested cases. Expression of the cytotoxic granule protein @entity10807 was noted in a majority of @entity5 cells in only three of 16 tested cases. We conclude that approximately half of @entity405 + @entity784 clinically and histologically resemble @entity404 + @entity4888 / @entity14041 , whereas presentation as @entity75 are more common in @entity405 + @entity5 as compared to those that express @entity404 .

title: Clinical and pathological spectrum of @entity405 -positive XXXX .

entities_list: @entity4888 :: ('MESH:D009182', 'Disease') :: ['mycosis fungoides', 'MF']

entities_list: @entity33835 :: ('MESH:D056267', 'Disease') :: ['pagetoid reticulosis', 'PR']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'epidermotropic tumor', 'T-cell tumors', 'tumors']

entities_list: @entity2617 :: ('MESH:D017254', 'Disease') :: ['Prominent periadnexal infiltration']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell lymphomas', 'cutaneous T-cell lymphomas']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['discrete nodular lesions']

entities_list: @entity14041 :: ('MESH:D012751', 'Disease') :: ['SS', 'Sezary syndrome']

entities_list: @entity5658 :: ('MESH:D003873', 'Disease') :: ['erythroderma']

answer: @entity784 :: (MESH:D016399,Disease) :: ['cutaneous T-cell lymphomas']


abstract: BACKGROUND: @entity661 ( @entity661 ) is a poorly understood condition associated with periods of emotional and physical stress. The clinical approaches for management of @entity661 are supportive and reactive to @entity1 symptoms. OBJECTIVE: To utilize next-generation exome sequencing to define genetic variation associated with, and potentially responsible for, this disease. METHODS: We performed exome sequencing of 7 white female @entity1 with @entity661 . Filtering of the identified variants was performed to limit our investigation to those sequences that passed quality control criteria, were rare or novel, were determined algorithmically to have high impact on the associated protein, and were within regions of high species conservation. All variants were verified by using Sanger sequencing. RESULTS: Exome-sequencing analysis revealed that each @entity1 carried predicted deleterious variants affecting known @entity296 genes. In each case, the identified variant was either not previously found in public @entity1 genome data or was previously annotated in a database of clinical variants associated with @entity299 . CONCLUSION: @entity1 with @entity661 harbor deleterious mutations in established @entity296 genes at a level higher than healthy controls. We hypothesize that @entity1 at highest risk for @entity661 likely live in a compensated state of @entity299 that manifests clinically only after the myocardium is stressed. In short, we propose that @entity661 is another example of an @entity296 with a distinct physiological trigger and suggest that alternative clinical approaches to these @entity1 may be warranted. ABBREVIATIONS: CADD, Combined Annotation Dependent DepletionFPKM, fragments per kilobase pair of exon per million fragments mappedNHLBI GO ESP, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing ProjectPCR, polymerase chain reactionSIC, stress-induced @entity296 .

title: Rare Variants in XXXX Genes Associated With Stress-Induced @entity296 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients', 'patient']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy', 'occult cardiomyopathy']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['SIC', 'Stress-induced cardiomyopathy']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac dysfunction']

answer: @entity296 :: (MESH:D009202,Disease) :: ['Cardiomyopathy']


abstract: @entity158 is the most common reason why @entity1 see a physician. Within the USA, it has been estimated that at least 116 million US adults suffer from @entity1118 , with an estimated annual national economic cost of  560-635 billion. While @entity158 is in part a sensory process, like sight, touch, or smell, @entity158 is also in part an emotional experience, like @entity308 , @entity148 , or anger. Thus, @entity1118 is arguably the quintessential biopsychosocial condition. Due to the overwhelming evidence of the biopsychosocial nature of @entity158 and the value of psychological assessments, the majority of @entity1118 guidelines recommend a psychological evaluation as an integral part of the diagnostic workup. One biopsychosocial inventory designed for the assessment of @entity1 with @entity1118 is the Battery for Health Improvement 2 (BHI 2). The BHI 2 is a standardized psychometric measure, with three validity measures, 16 clinical scales, and a multidimensional assessment of @entity158 . This article will review how the BHI 2 was developed, BHI 2 concepts, validation research, and an overview of the description and interpretation of its scales. Like all measures, the BHI 2 has strengths and weaknesses of which the forensic psychologist should be aware, and particular purposes for which it is best suited. Guided by that knowledge, the BHI 2 can play a useful role in the forensic psychologist's toolbox.

title: The Psychological Evaluation of XXXX with @entity1118 : a Review of BHI 2 Clinical and Forensic Interpretive Considerations.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: BACKGROUND: Some @entity1 with @entity3271 have generalized @entity410 (GTCS) while others have only partial @entity410 (PS). We investigated the relationship between @entity5 localization and @entity410 generalization using quantitative lesion mapping on magnetic resonance images. METHODS: Twenty one @entity1 with histologically proven @entity3271 and GTCS (n=11) or PS (n=10) were studied. Data were acquired on a 3 Tesla MRI System. We performed lesion mapping techniques to compare the spatial distribution of @entity3271 between @entity1 groups, and quantitatively determined the extent to which lesions intersected each probabilistic regions-of-interest, including the cerebral lobes, thalamus, striatum, and genu of the corpus callosum. RESULTS: In @entity1 experiencing GTCS, the greatest lesion load was observed in mesial frontal regions, including cortex connected to the genu. In contrast, the greatest lesion load in @entity1 experiencing PS was observed more caudo-laterally in orbitofrontal and temporal lobes, but typically sparing cortex connected to the genu. The number of lesion intersections with genu region of interest was significantly greater in @entity1 experiencing GTCS relative to @entity1 with PS (p=0.03). There were no significant differences between @entity1 groups with respect to lesion intersection with the individual cerebral lobes, thalamus and striatum, or with respect to overall @entity3271 size. CONCLUSION: Our data suggest that the genu of the corpus callosum may be a major pathway for @entity410 generalization in @entity1 with @entity3271 .

title: The role of the corpus callosum in XXXX spread: MRI lesion mapping in @entity3271 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures', 'tonic-clonic seizures']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity3271 :: ('MESH:D009837', 'Disease') :: ['oligodendrogliomas', 'oligodendroglioma']

answer: @entity410 :: (MESH:D012640,Disease) :: ['seizure']


abstract: The class II (Ia) MHC molecules are cell surface proteins that regulate the activation of T cells. B lymphocyte expression of class II molecules has been shown to be influenced by a number of external stimuli. It has been previously demonstrated that treatment of these cells with @entity58 leads to an increase in class II gene transcription at 18 h as well as to an increase in steady state class II mRNA. It has also been previously demonstrated that @entity558 treatment of splenic B cells from athymic @entity19 results in a decrease in steady state mRNA encoding the @entity56389 class II protein. This decrease persists for at least 18 h. Nuclear run-on transcription assays now demonstrate that although steady state mRNA levels for @entity56389 are decreased by @entity558 treatment of athymic @entity19 lymphocytes, @entity558 does not decrease @entity56389 gene transcription, but rather modestly activates transcription of this class II gene. @entity558 and @entity58 have been demonstrated to be synergistic stimuli for a number of genes. Costimulation of splenic lymphocytes from athymic @entity19 with @entity58 plus @entity558 leads to activation of transcription, but the increase in transcription is no more than that seen with @entity58 stimulation alone. However, in costimulated lymphocytes, steady state @entity56389 -encoding mRNA levels are intermediate between the increased levels seen with @entity58 stimulation and the decreased levels seen with @entity558 stimulation. Therefore, @entity558 and @entity58 act nonsynergistically in class II gene transcription and the effects of @entity558 in decreasing steady state mRNA are most likely posttranscriptional. An @entity58 -inducible and an @entity558 -inducible @entity19776 have been previously identified in splenic lymphocytes from athymic @entity19 . Both nuclear binding proteins form complexes with the same DNA fragments from a control region of the @entity56389 gene. These nucleoprotein complexes comigrate under nondenaturing conditions and display identical patterns of binding with a panel of oligonucleotide competitors. Oligonucleotides representing protein binding sites of the @entity58 and @entity558 -induced DNA-binding proteins cross-compete for protein binding. Therefore, the binding proteins induced by @entity558 and @entity58 are likely related, and may function at different efficiencies as activators of @entity56389 gene transcription.

title: Role of lipopolysaccharide and XXXX in control of transcription of the class II @entity56389 gene.

answer: @entity58 :: (16189(Tax:10090),Gene) :: ['IL-4']


abstract: OBJECTIVE: To study the effects of an acute therapeutic oral intake of @entity2263 ) agonist on performance and substrate response during supramaximal exercise in @entity1 . METHODS: 12 healthy moderately trained female volunteers performed a Wingate test after ingestion of placebo ( @entity1989 ) and @entity3045 ( @entity2697 ; 4 mg) according to a double-blind randomised crossover study. Blood samples were collected at rest, at the end of exercise and after 5 (r5), 10 (r10) and 15 (r15) min of passive recovery for @entity4545 (ACTH), @entity2124 ( @entity2124 ), insulin, blood @entity413 and @entity880 measurements. RESULTS: Peak power (PP) and mean power (MP) significantly increased whereas time to peak power was significantly shorter with @entity2697 than with @entity1989 (p<0.05). No change was observed in the fatigue index. ACTH was not significantly modified but r15 @entity2124 significantly decreased (p<0.05) after the intake of @entity2697 . Both @entity1503 and blood @entity413 were significantly increased by the intake of @entity2697 during all the experiments (p<0.01). Blood @entity880 was significantly increased by the intake of @entity2697 compared with that of @entity1989 (p<0.05) after 10 and 15 min of passive recovery. CONCLUSION: From these data, acute therapeutic oral intake of @entity2697 seems to induce, irrespective of the subjects' gender, an improvement in performance during a supramaximal exercise--that is, increase in PP and MP. Further studies are necessary to clarify whether the mechanisms involved in the response to intake of @entity2697 are linked to central and/or peripheral pathways.

title: Effects of acute XXXX intake during supramaximal exercise in @entity1 .

entities_list: @entity4545 :: ('5443', 'Gene') :: ['adrenocorticotropic hormone']

entities_list: @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity3045 :: (MESH:D000420,Chemical) :: ['salbutamol']


abstract: BACKGROUND: Two types of @entity470 ( @entity470 ) mutations in exon 19 and exon 21 (ex19del and @entity9512 ) are prevalent in @entity2 @entity1 and sensitive to targeted @entity470 inhibition. A resistance mutation in exon 20 ( @entity9513 ) has been found to accompany drug treatment when @entity1 relapse. These three mutations are valuable companion diagnostic biomarkers for guiding personalized treatment. Quantitative polymerase chain reaction (qPCR)-based methods have been widely used in the clinic by physicians to guide treatment decisions. The aim of this study was to evaluate the technical and clinical sensitivity and specificity of the droplet digital polymerase chain reaction (ddPCR) method in detecting the three @entity470 mutations in @entity1 with @entity2 . METHODS: Genomic DNA from H1975 and PC-9 cells, as well as 92 normal @entity1 blood specimens, was used to determine the technical sensitivity and specificity of the ddPCR assays. Genomic DNA of @entity406 -fixed, @entity982 -embedded specimens from 78 Chinese @entity1 with @entity2220 were assayed using both qPCR and ddPCR. RESULTS: The three ddPCR assays had a limit of detection of 0.02% and a wide dynamic range from 1 to 20,000 copies measurement. The @entity9512 and ex19del assays had a 0% background level in the technical and clinical settings. The @entity9513 assay appeared to have a 0.03% technical background. The ddPCR assays were robust for correct determination of @entity470 mutation status in @entity1 , and the dynamic range appeared to be better than qPCR methods. The ddPCR assay for @entity9513 could detect @entity1 samples that the qPCR method failed to detect. About 49% of this @entity1 cohort had @entity470 mutations ( @entity9512 , 15.4%; ex19del, 29.5%; @entity9513 , 6.4%). Two @entity1 with the ex19del mutation also had a na  ve @entity9513 mutation. CONCLUSION: These data suggest that the ddPCR method could be useful in the personalized treatment of @entity1 with @entity2 .

title: Detection of XXXX mutation in @entity2 by droplet digital polymerase chain reaction.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient']

entities_list: @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']

answer: @entity470 :: (1956,Gene) :: ['epidermal growth factor receptor']


abstract: OBJECTIVE: Investigate the expression and significance of @entity1712 in @entity3377 . METHODS: Retrospective analysis of clinical data for 151 @entity3377 @entity1 (BR group), complete blood count and blood bacterial culture etc.; in addition, 150 general @entity2348 @entity1 (BI group) and 135 @entity1 in healthy physical condition upon testing (NC group) are selected respectively as the control groups to comparatively study expression of white blood cells and @entity1712 for @entity3377 @entity1 . Adopt t test to compare measurement data. RESULTS: In comparison with BI group, WBC, NE, EO, MO, NE% and EO% in BR group are reduced but LY, LY% and MO% are increased and such difference shows statistical significance (P<0.01). In comparison with NC group, difference of WBC and NE in BR group shows no statistical significance (P>0.05). NE%, EO and EO% are reduced but MO, LY% and MO% are increased and such difference shows statistical significance (P<0.01). LY is increased and the difference shows statistical significance (P<0.05). White blood cell count is normal or is reduced among most of @entity3377 @entity1 , accounting for 90.73% (137/151); the @entity1 whose @entity1712 are reduced account for 75.50% (114/151) and those whose @entity1712 disappear are about 18.54% (28/151). CONCLUSION: There is an incidence rate of @entity1712 decrease or disappearance in @entity3377 and it shows the indication significance in the diagnosis of @entity66 .

title: Expression of @entity1712 be beneficial to early clinical diagnosis of XXXX .

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophils']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity3377 :: ('MESH:D002006', 'Disease') :: ['brucellosis', 'Brucellosis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['early disease']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infection']

answer: @entity3377 :: (MESH:D002006,Disease) :: ['brucellosis']


abstract: OBJECTIVES: The aim of our study is to analyze the clinicopathological characteristics and treatment options for @entity7172 with multifocality and investigated whether the number of foci in @entity7172 with multifocality can predict central lymph node @entity3 . Methods Records of 329 consecutive PTMC @entity1 with multifocality, and who were treated surgically between 2003 and 2014 were reviewed. @entity1 with multifocality were identified by histopathology. The number of foci, size of the @entity5 , presence of extrathyroidal invasion, infiltration, and other clinicopathological parameters were collected and analyzed for all the cases. RESULTS: Univariate analysis, age, sex, maximum @entity5 size, and extrathyroidal invasion were found to be significant prognostic factors (P = 0.001, 0.020, < 0.001, 0.043; respectively). Multivariate analysis found that age, sex, and maximum @entity5 size were independent prognostic factors for CLNM in PTMCs. Among them, Male @entity1 (odds ratio 1.887; 95% confidence interval [CI] 1.053-3.380) and with maximum @entity5 size > 0.5 cm (odds ratio 2.819; 95% CI 1.721-4.616) were risk factors for increased incidence of CLNM. @entity1 >=  45 years (odds ratio 0. 497; 95% CI 0.309-0.800) were less likely to present with CLNM. However, extrathyroid invasion was not an independent predictor of CLNM according to our results. PTMCs with 2, 3, >=  4 foci had a significantly greater risk of CLNM (odds ratio 1.675, 2.360, 2.703; 95% CI 1.195-2.347, 1.425-3.906, 1.411-5.178; respectively) compared to PTMCs with unifocality. CONCLUSIONS: Foci numbers were linked to an increased incidence of central lymph node @entity3 in @entity7172 with multifocality, and we could choose to perform more radical treatment in @entity1 with multifocality.

title: Using foci number to predict central lymph node @entity3 of XXXX with multifocality.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['largest tumour', 'tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity7172 :: ('MESH:C563277', 'Disease') :: ['papillary thyroid microcarcinomas']

answer: @entity7172 :: (MESH:C563277,Disease) :: ['papillary thyroid microcarcinomas']


abstract: BACKGROUND _ AIMS: @entity3851 ( @entity3851 ) score has been extensively used to prioritize @entity1 for liver transplantation and determine their prognosis, but with limited predictive value. @entity5433 may correlate with increased mortality after liver transplant. In this study, two autonomic biomarkers, complexity and deceleration capacity, were added to the predicting model for 1-year mortality after liver transplantation. METHODS: In all, 30 @entity1 with end-stage @entity409 awaiting liver transplantation were included. Complexity and deceleration capacity were calculated by multi-scale entropy and phase-rectified signal averaging, respectively. Different combinations of autonomic factors and @entity3851 score were used to predict mortality rate of liver transplant after 1-year follow-up. Receiver-operating characteristics curve analysis was performed to determine clinical predictability. Area under the receiver-operating characteristics curve represents the overall accuracy. RESULTS: The 1-year mortality rate was 16.7% (5/30). The overall accuracy of @entity3851 score used for predicting mortality after liver transplantation was 0.752. By adding complexity and deceleration capacity into the predicting model, the accuracy increased to 0.912. Notably, the accuracy of the prediction using complexity and deceleration capacity alone was 0.912. CONCLUSION: Complexity and deceleration capacity, which represent different dynamical properties of a @entity1 autonomic system, are critical factors for predicting mortality rate of liver transplantation. We recommend that these pre-operative autonomic factors may be helpful as critical adjuncts to predicting model of mortality rate in prioritizing organ allocation.

title: The role of XXXX in predicting 1-year mortality after liver transplantation.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity5433 :: ('MESH:C563939', 'Disease') :: ['Autonomic dysfunction']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver diseases']

entities_list: @entity3851 :: ('MESH:D058625', 'Disease') :: ['MELD', 'Model for end-stage liver disease']

answer: @entity5433 :: (MESH:C563939,Disease) :: ['autonomic dysfunction']


abstract: OBJECTIVE: @entity29940 (Lotronex), a potent selective @entity750 (3) receptor antagonist, was approved in February, 2000 in the United States for the treatment of @entity294 -predominant @entity1744 ( @entity1744 ) in @entity1 . Marketing was suspended in November, 2000, after reports of @entity63 and serious complications of @entity1142 . We sought to compare the incidence of @entity63 , hospitalized complications of @entity1142 , and bowel surgery among alosetron users and a cohort of @entity1 with @entity1744 who did not use @entity29940 . METHODS: We sought outcomes of @entity63 , hospitalized complications of @entity1142 , and bowel surgery in 3,631 Lotronex users and 2,480 comparison @entity1744 subjects using diagnoses, procedures, and drugs recorded in the UnitedHealthcare insurance claims database, and validated these by chart review. The initial assessment was to last for 3 yr beginning with the start of alosetron treatment and was to include 10,000 Lotronex users; however, the observation period ended by December 31, 2000, after suspension of marketing. RESULTS: There were 3631 alosetron users among members of UnitedHealthcare from March through December, 2000, and we identified 2480 comparison @entity1744 -only @entity1 ; follow-up time averaged about 5 months in both groups. There were no instances of @entity63 in either cohort. Thirty instances of bowel surgery occurred, giving rates of 10.2/1000 @entity1 -yr in the alosetron cohort and 11.8/1000 @entity1 -yr in the @entity1744 /no alosetron cohort. There were three cases of hospitalized complications of @entity1142 . The incidence rates were essentially the same in alosetron users (1.24/1000 @entity1 -yr) and in @entity1744 @entity1 with no alosetron use (0.92/1000 @entity1 -yr). CONCLUSIONS: Alosetron users did not differ from @entity1744 @entity1 not using alosetron in the incidence of bowel surgery or hospitalized complications of @entity1142 ; there were no cases of @entity63 . The statistical upper limit of @entity63 rates in alosetron users was 2.28/1000 @entity1 -yr. Because of the market withdrawal, the size of the cohort and the duration of follow-up were smaller than originally planned; consequently, the statements about the safety of alosetron were necessarily limited. On June 7, 2002, the Food and Drug Administration approved alosetron for reintroduction in the U.S. market for @entity1 with severe @entity294 -related @entity1744 .

title: Incidence of @entity63 , hospitalized complications of @entity1142 , and bowel surgery in relation to use of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'person']

entities_list: @entity29940 :: ('MESH:C090840', 'Chemical') :: ['alosetron', 'Alosetron hydrochloride']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['colonic ischemia']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['5-hydroxytryptamine']

entities_list: @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome', 'IBS']

answer: @entity29940 :: (MESH:C090840,Chemical) :: ['alosetron hydrochloride']


abstract: @entity2109 ( @entity2109 ) features translocations linking c-myc to an Ig locus. Breakpoints in the H chain locus ( @entity7528 ) stand either close to J(H) or within switch regions and always link c-myc to the 3' @entity7528 locus control region (3' LCR). To test the hypothesis that the 3' LCR alone was sufficient to deregulate c-myc, we generated @entity19 carrying a 3' LCR-driven c-myc transgene and specifically up-regulating c-myc in B cells. Splenic B cells from @entity19 proliferated exaggeratedly in response to various signals had an elevated apoptosis rate but normal B220/IgM/IgD expression. Although all Ig levels were lowered in vivo, class switching and Ig secretion proved normal in vitro. Beginning at the age of 12 wk, @entity19 developed @entity981 with an overall incidence of 80% by 40 wk. @entity981 were B220(+)IgM(+)IgD(+) with the @entity2109 "starry sky" appearance. Gene expression profiles revealed broad alterations in the proliferation program and the Ras-p21 pathway. Our study demonstrates that 3' @entity7528 enhancers alone can deregulate c-myc and initiate the development of @entity706 . The rapid and constant occurrence of @entity706 in this model makes it valuable for the understanding and the potential therapeutic manipulation of c-myc oncogenicity in vivo.

title: The 3' XXXX locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['clonal lymphoblastic lymphomas or diffuse anaplastic plasmacytomas', 'Lymphoblastic lymphomas']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'BL-like lymphomas']

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'transgenic mice']

entities_list: @entity2109 :: ('MESH:D002051', 'Disease') :: ['Burkitt lymphoma', 'BL']

answer: @entity7528 :: (111507(Tax:10090),Gene) :: ['IgH']


abstract: OBJECTIVES: @entity1118 and long-term opioid use may lead to a persistent deficit in hedonic capacity, characterized by increased sensitivity to aversive states and insensitivity to natural rewards. Dispositional mindfulness has been linked with improved emotion regulation and @entity158 coping. The aim of the current study was to examine associations between dispositional mindfulness, hedonic capacity, and @entity158 -related interference in an opioid-using @entity1118 sample. METHODS: Data were obtained from a sample of 115 @entity1118 @entity1 on long-term opioid therapy (68% females, M age=48.3, SD=13.6) who completed the Five Facet Mindfulness Questionnaire (FFMQ), the Snaith-Hamilton Anhedonia and Pleasure Scale (SHAPS), the Brief Pain Inventory, and a psychiatric assessment of major @entity308 . Bivariate correlations, hierarchical multiple regression, and path analysis were used to determine whether dispositional mindfulness scores (FFMQ) predicted variance in hedonic capacity (SHAPS), and whether hedonic capacity mediated the association between mindfulness and @entity158 interference. RESULTS: We observed a significant positive correlation between dispositional mindfulness and hedonic capacity scores (r=0.33, P<0.001). Hierarchical regression indicated that after controlling for @entity158 interference and major @entity308 diagnosis, dispositional mindfulness explained a significant portion of variance in hedonic capacity (b=0.30, P<0.01). The association between dispositional mindfulness and @entity158 interference was mediated by hedonic capacity ( @entity69015 , @entity69016 ; 95% CI, -0.004 to -0.024, full model R=0.39). DISCUSSION: Findings indicate that dispositional mindfulness was associated with hedonic capacity among this @entity1118 sample. In light of this association, it is plausible that interventions that increase mindfulness may reduce @entity158 among opioid-using @entity1 by enhancing hedonic capacity.

title: Mindfulness is Associated With Increased Hedonic Capacity Among @entity1118 XXXX Receiving Extended Opioid Pharmacotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive disorder', 'depression']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'pain-related impairment']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['Chronic pain', 'chronic pain']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: @entity1 with @entity161 , who have disturbances in mood, thought processes and behavior, experience impairment in day-to-day functioning. Primary caregivers have tried to become involved in caring for @entity1 with @entity161 by coordination with community @entity146 nurses. Community @entity146 nurses have an important role to play in supporting families in this care, especially primary caregivers. The purpose of the present study was to explore the relationship between Thai community @entity146 nurses and primary caregivers of @entity1 with @entity161 . Grounded theory methodology was used to examine the process with which community @entity146 nurses work together with primary caregivers. Purposive sampling and theoretical sampling were used. Data were collected from 34 informants, including 17 community @entity146 nurses and 17 primary caregivers through in-depth interviews, observation, and field notes. Data was analyzed using constant and comparative methods by Glaser (1978). The study revealed that building collaboration in the care of @entity1 with @entity161 involved coordinating both community @entity146 nurses and primary caregivers in a process that consists of five major stages. In the first stage, community @entity146 nurses and primary caregivers used strategies to establish trust in each other before the next stage, which engaged their concerns and needs. Later, the stages of mutual preparation for caregiving, cooperating on @entity1 care and monitoring outcomes were jointly employed in order to promote a healthy family life for @entity1 . The study concludes by suggesting guidelines and giving insights into ways of helping primary caregivers and their @entity1 with @entity161 .

title: Building collaboration in caring for @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'people', 'persons', 'People']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: OBJECT: @entity11369 affects one in 10 @entity1 born to mothers who ingest @entity1092 regularly during pregnancy. It has been described as producing a combination of typical @entity154 and major @entity3002 . @entity91 is caused by premature fusion of the metopic suture and has not previously been described as a typical feature of the syndrome. The authors reviewed the cases of 2,220 @entity1 with @entity91 to examine the effect of maternal @entity1092 use on the fetus. METHODS: Case files of all 2,220 @entity1 were reviewed. The type and severity of each @entity1 's @entity91 was assessed. Information about maternal health and medication use was obtained, and family interviews were conducted. @entity1 underwent mental development assessment performed using standard tests both pre- and postoperatively. Detailed maternal health information was obtained in 1,676 cases. Of these, 17 mothers were found to have undergone regular treatment with @entity1092 monotherapy at the time of their pregnancies. No other antiepileptic medical regimen was found. All 17 @entity1 exhibited @entity91 . These @entity1 ' intelligence quotients (JQs) at the time of the most recent follow-up examination ranged from 45 to 100, with a mean of 75; IQs were significantly higher in @entity1 who underwent surgery before reaching 6 months of age. CONCLUSIONS: Ideally any pregnancy in a @entity1 being treated for @entity302 should be planned, and both an obstetrician and a neurologist should be consulted. In @entity1 born with @entity11369 , it is important to be aware of the possibility of metopic suture synostosis, which we believe should be considered part of the syndrome, because early surgical intervention may improve cognitive outcome.

title: XXXX and fetal exposure to @entity1092 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'woman', 'patients', 'Children', 'patient']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['dysmorphic features']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['sodium valproate']

entities_list: @entity3002 :: ('MESH:D009421', 'Disease') :: ['organ system anomalies']

entities_list: @entity11369 :: ('MESH:C536525', 'Disease') :: ['Fetal valproate syndrome', 'fetal valproate syndrome']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity91 :: ('MESH:D003398', 'Disease') :: ['Trigonocephaly', 'craniosynostosis', 'trigonocephaly']

answer: @entity91 :: (MESH:D003398,Disease) :: ['Craniosynostosis']


abstract: OBJECTIVES: The study evaluated the outcome of the treatment of @entity1 who sustained high-energy, compression-type injuries of the distal radius. DESIGN: The retrospective study evaluated the outcome of reduction and plating of the lunate facet in conjunction with standard external fixation. SETTING: A Level I @entity130 center. @entity1 : Inclusion criteria for study participation included: 1) age between 18 and 65 years of age with no evidence of concomitant @entity2331 ; and 2) a 3- or 4-part compression type @entity174 of the distal radius with residual displacement of the palmar lunate facet despite reduction of the dorsal cortex by the application of an external fixator. INTERVENTION: @entity174 were treated with palmar plating of the depressed lunate facet combined with dorsal external fixation. MAIN OUTCOME MEASUREMENTS: Posttreatment evaluations consisted of measurements of range of motion, grip strength, radiographic evaluations, and completion of Disability of Arm, Shoulder, and Hand questionnaires. RESULTS: Three months after surgery, 20 of 21 @entity1 exhibited full range of motion at the @entity806 / @entity4552 joints. At the 2-year follow-up, an average palmar tilt of +1.0 degrees, radial inclination of 24 degrees, radial length of 12 mm, ulnar variance of 0.5 mm, intra-articular gap of 0.1 mm, and intra-articular step-off of 0.3 mm was documented. Using the Garland and Werley rating system, results were rated as excellent or good for 18 wrists, fair for 2 wrists, and poor for 1 wrist. Mean Disability of Arm, Shoulder, and Hand functional scores and athletic scores improved at 6 months. CONCLUSIONS: Reduction and plating of the lunate facet in conjunction with standard external fixation permits: 1) visualization and reduction of the palmar lunate facet; and 2) reduction of palmar tilt to neutral tilt without significant radial shortening. This technique should be considered as an acceptable option in the treatment of high-energy @entity174 of the distal radius.

title: Results of palmar plating of the lunate facet combined with external fixation for the treatment of high-energy compression XXXX of the distal radius.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'fracture', 'Fractures']

entities_list: @entity2331 :: ('MESH:D001851', 'Disease') :: ['metabolic bone disease']

answer: @entity174 :: (MESH:D050723,Disease) :: ['fractures']


abstract: @entity1024 receptors (NRs) play an important role in basal ganglia function. By using in situ hybridization with @entity2151 probes, we investigated the regional and cellular distribution of NR subunit mRNA expression in the @entity1 basal ganglia: caudate nucleus, putamen, lateral globus pallidus (LGP), and medial globus pallidus (MGP). Analysis of both film autoradiograms and emulsion-dipped slides revealed distinct distribution patterns for each subunit. On film autoradiograms, the signal for @entity6806 , @entity13069 , and @entity21413 in the striatum (STR) was higher than in globus pallidus (GP). The @entity21412 probe gave a stronger signal in GP than in STR. For @entity11588 we found a signal in all regions. Analysis of emulsion-dipped sections demonstrated that in striatal neurons, the @entity13069 signal was higher than in GP neurons. In GP neurons, @entity21412 was more abundant than in striatal neurons. Despite the relatively low signal on film for @entity21413 in GP, we found a slightly higher signal in GP per neuron than in STR since in the pallidal areas neurons were sparse but intensely labeled. @entity6806 and @entity11588 were more evenly distributed over neurons of STR and GP Between the different parts of STR and GP, we observed only minor differences in the expression of NRs. In MGP a subpopulation of neurons exhibiting low @entity21412 signals could be separated from the majority of neurons showing an intense @entity21412 signal. Since the physiological properties of NRs are dependent on subunit composition, these data suggest a high degree of regional specialization of NR properties in the @entity1 basal ganglia.

title: Expression of @entity1024 receptor subunit mRNAs in the XXXX brain: striatum and globus pallidus.

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate']

entities_list: @entity2151 :: ('CHEBI:26561', 'Chemical') :: ['ribonucleotide']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The increase of laparoscopic cholecystectomy has resulted in an increase of @entity1157 . The purpose of this article is to define the types of injury, their occurrence and frequency, and their management by endoscopic and surgical techniques. Three investigations were included in the present study. 1. A 3-year retrospective study among 29 hospitals with 25,007 laparoscopic cholecystectomies. 2. An 8-year prospective study at our institution of 6488 @entity1 . 3. A prospective endoscopic study of 94 @entity1 with injuries and strictures of the common bile duct (CBD) after laparoscopic cholecystectomy. A special classification for @entity1157 was developed. Among 25,007 @entity1 from 29 hospitals, a total of 74 lesions were detected with an incidence of 0.29%. At our institution, 20 cases were seen (0.29%) with type I, II, and III injuries. The 94 cases managed by endoscopic procedure were submitted to endoscopic retrograde cholangiopancreatography (ERCP) and papillotomy, with placement of several stents 5 to 10 F during 8 months. The results of this procedure have been excellent to good in 76% of the cases up to 3 years of follow-up. According to our previous and present experience, @entity1157 after laparoscopic procedure are two times higher than after open procedure. The best treatment is the prevention of these injuries by careful surgical technique. If they occur, the best moment to repair them is during surgery. If they are noticed after the operation, endoscopic or surgical procedures can be employed.

title: Treatment of common XXXX during laparoscopic cholecystectomy: endoscopic and surgical management.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1157 :: ('MESH:D001649', 'Disease') :: ['bile duct injuries']

answer: @entity1157 :: (MESH:D001649,Disease) :: ['bile duct injuries']


abstract: PURPOSE: To determine the incidence, predictors, and outcomes of generalized @entity159 (GCSE) in @entity131 ( @entity131 ) @entity1 . METHODS: We conducted a retrospective cross-sectional study of adult @entity1 with acute @entity131 using the 2002-2010 Nationwide Inpatient Sample (NIS) database of USA. We used multivariable logistic regression analyses to identify independent predictors of GCSE in @entity1 with @entity131 and to determine the impact of GCSE on outcomes (in-hospital mortality, length of stay, total hospital charges, and discharge disposition). RESULTS: Among 1,457,869 @entity1 hospitalized with @entity131 , 2315 (0.16%) had GCSE. In-hospital mortality was significantly higher in @entity1 with GCSE (32.5% vs. 9.6%; unadjusted OR 4.54, 95% CI 4.16-4.96; p<0.001; adjusted OR 3.41; 95% CI 3.09-3.76p<0.001). @entity1 with GCSE had longer length of stay (17.3  21.9 vs. 6.8  11.1 days; p<0.001), higher total hospital charges ( 147,415  162,319 vs.  54,041  90,524; p<0.001), and were less likely to be discharged home (19.8% vs. 52.7%; p<0.001). Using multivariable logistic regression analysis, age >35 years (OR 2.15; 95% CI 1.87-2.47), CNS @entity281 (OR 4.86; 95% CI 3.70-6.38), @entity1545 (OR 9.54; 95% CI 8.10-11.22), and acute @entity385 (OR 4.09; 95% CI 3.41-4.87) were independent predictors of GCSE in @entity131 @entity1 . @entity302 was an independent negative predictor of GCSE (OR 0.74; 95% CI 0.55-0.99). CONCLUSION: Despite its low incidence, GCSE in @entity131 @entity1 was associated with worse outcomes with threefold higher in-hospital mortality, prolonged hospitalization, higher hospital charges, and worse discharge disposition. Surprisingly, @entity302 is a negative predictor of GCSE in this population.

title: A retrospective cross-sectional study of the prevalence of generalized @entity159 in XXXX : United States 2002-2010.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1545 :: ('MESH:D020214', 'Disease') :: ['anoxic brain injury']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'Epilepsy']

entities_list: @entity159 :: ('MESH:D013226', 'Disease') :: ['convulsive status epilepticus']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity131 :: (MESH:D001930,Disease) :: ['traumatic brain injury']


abstract: UNASSIGNED: The present study examined the effects of dietary @entity3264 ( @entity7647 ) on the growth, intestinal function, immunity and antioxidant capacity of sea @entity9688 @entity20874 (Selenka). The specific growth rate, intestinal morphology, activity of digestive enzymes, activity and gene expression of lysozyme and antioxidative enzymes of the sea @entity9688 were determined after feeding 5 experimental diets with additions of increasing levels of @entity7647 (at 0%, 0.4%, 0.8%,1.2% and 1.6%, respectively) for 60 days. We discovered that the specific growth rate of the sea @entity9688 in 0.4%, 0.8% and 1.2% groups increased 35.3%, 27.3% and 24.1%, respectively, compared to the control (0%) group with significant differences. Dietary @entity7647 can improve the intestinal function of the sea @entity9688 by increasing the activities of trypsin and @entity70115 in the intestine and the villus height and villus density of the intestine, eventhough significant differences were not observed in some groups. 0.4%-0.8% of dietary @entity7647 can significantly increase the activity of lysozyme (LSZ) in the coelomic fluid of the sea @entity9688 . Significant improvements were observed on the SOD activity in coelomic fluid of the sea @entity9688 fed diets supplemented with 0.4%-1.6% of @entity7647 compared to the control group. Similarly, the @entity70116 activity in coelomic fluid of the sea @entity9688 significantly increased in 0.8%, 1.2% and 1.6% groups compared to the control and 0.4% groups. Change pattern of the activity of @entity70116 was consistent with the change pattern of the expression of @entity70116 gene, indicating the dietary @entity7647 can up-regulate the expression of @entity70116 gene and consequently promote the secretion of @entity70116 . However, the down-regulation of the expression of SOD gene by dietary @entity7647 were observed in almost all of the treatment groups, which is in contrast with the change pattern of the activity of SOD, indicating the negative feedback regulation of the secretion of SOD on the expression of SOD gene. In summary, the suitable supplementation levels of @entity7647 in diets of sea @entity9688 A.  japonicus are 0.4%-0.8%, based on the effectiveness of dietary @entity7647 on the growth, intestinal function, immunity and antioxidant capacity of the sea @entity9688 .

title: Regulation of dietary @entity3264 on the growth, intestinal function, immunity and antioxidant capacity of sea @entity9688 XXXX (Selenka).

entities_list: @entity20874 :: ('307972', 'Species') :: ['Apostichopus japonicus']

entities_list: @entity9688 :: ('3659', 'Species') :: ['cucumber', 'cucumbers']

answer: @entity20874 :: (307972,Species) :: ['Apostichopus japonicus']


abstract: BACKGROUND: The fifth edition of the Diagnostic and Statistical Manual of @entity146 ( @entity4987 ) was published in May 2013. @entity72 ( @entity72 ) has been structured for the three subtypes of @entity245 ( @entity245 ), but the number of impairment in social and communication dimension is not stated. METHODS: The subjects were 68 @entity1 who visited the Department of Psychology and Development at Nagoya City University Hospital for the first time between the ages of 6 and 15 years old. We retrospectively re-examined the subjects using DSM-IV-TR criteria and @entity4987 criteria with two rules (two of three and one of three on the social and communication dimension) and examined the concordance rate. RESULTS: Forty subjects were diagnosed with @entity245 , and 28 were not. The mean @entity245 subject age was 9.4   years, and mean IQ was 84.0 on the Wechsler Intelligence Scale for @entity1 III or 62.7 on the Tanaka-Binet test. Twenty-seven (68%) of the @entity245 subjects were classified with @entity72 using @entity4987 criteria when the two of three rule was applied, while 32 (80%) were classified with @entity72 when the one of three rule was applied. All subjects without @entity245 were not diagnosed with @entity72 on @entity4987 criteria. CONCLUSION: @entity4987 criteria may exclude high functioning and older subjects from @entity72 because they tend to be atypical. The diagnostic procedure for @entity4987 criteria is ambiguous, especially in high functioning subjects and those diagnosed at an older age.

title: Concordance of @entity4987 and DSM-IV-TR classifications for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Mental Disorders']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['PDD', 'pervasive developmental disorder']

entities_list: @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'Autism spectrum disorder']

answer: @entity72 :: (MESH:D002659,Disease) :: ['autism spectrum disorder']


abstract: BACKGROUND: Despite considerable improvement in the treatment of advanced @entity43 , the optimization of efficacy and tolerability remains an important issue. Therefore, we performed a randomized, phase III non-inferiority trial comparing @entity1311 plus @entity900 (PT) with @entity1311 plus @entity3003 (TC) in @entity1 with advanced @entity43 . METHODS: A total of 798 @entity1 with International Federation of Gynecology and Obstetrics stage IIB-IV were randomly assigned to receive six courses of either PT or TC at 3-week intervals. The primary endpoint was the proportion of @entity1 without progression at 2 years. Secondary endpoints included @entity137 , response to treatment, quality of life, and overall and progression-free survival time. Quality of life was evaluated using the European Organization for Research and Treatment of @entity5 quality-of-life questionnaire (QLQ)-C30, version 2.0. Survival curves were calculated using the Kaplan-Meier method, and hazard ratios were estimated using the Cox proportional hazards model. RESULTS: The proportion of @entity1 without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%). Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different; the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively). The TC regimen was associated with a higher frequency of @entity1503 , but a lower frequency of @entity344 , than the PT regimen. Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68). CONCLUSION: The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in @entity1 with advanced @entity43 .

title: A randomized clinical trial of @entity900 / @entity1311 versus @entity3003 / XXXX as first-line treatment of @entity43 .

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal and neurologic toxicity']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity']

answer: @entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']


abstract: INTRODUCTION: Learning capacity may influence an individual's response to @entity2026 rehabilitation. However, investigations into the relationship between novel word learning ability and response to @entity5547 therapy are lacking. The aim of the present study was to evaluate the novel word learning ability in post- @entity64 @entity2026 and to establish the relationship between learning ability and @entity5547 treatment outcomes. We also explored the influence of locus of language breakdown on novel word learning ability and @entity5547 treatment response. MATERIAL AND METHODS: 30 adults (6F; 24M) with chronic, post- @entity64 @entity2026 were recruited to the study. Prior to treatment, @entity1 underwent an assessment of language, which included the @entity1650 Test and three baseline confrontation naming probes in order to develop sets of treated and untreated items. We also administered the novel word learning paradigm, in which @entity1 learnt novel names associated with unfamiliar objects and were immediately tested on recall (expressive) and recognition (receptive) tasks. @entity1 completed 48h of Aphasia Language Impairment and Functioning Therapy (Aphasia LIFT) over a 3 week (intensive) or 8 week (distributed) schedule. Therapy primarily targeted the remediation of word @entity51 , so naming of treated and untreated items immediately post-therapy and at 1 month follow-up was used to determine therapeutic response. RESULTS: Performance on recall and recognition tasks demonstrated that @entity1 were able to learn novel words; however, performance was variable and was influenced by @entity1 ' @entity2026 severity, lexical-semantic processing and locus of language breakdown. Novel word learning performance was significantly correlated with @entity1 ' response to therapy for treated items at post-therapy. In contrast, @entity1 ' novel word learning performance was not correlated with therapy gains for treated items at 1 month follow-up or for untreated items at either time point. Therapy intensity did not influence treatment outcomes. DISCUSSION: This is the first group study to directly examine the relationship between novel word learning and therapy outcomes for @entity5547 rehabilitation in adults with @entity2026 . Importantly, we found that novel word learning performance was correlated with therapy outcomes. We propose that novel word learning ability may contribute to the initial acquisition of treatment gains in @entity5547 rehabilitation.

title: The relationship between novel word learning and @entity5547 treatment success in adults with chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants']

entities_list: @entity1650 :: ('MESH:D001308', 'Disease') :: ['Comprehensive Aphasia']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['retrieval deficits']

answer: @entity2026 :: (MESH:D001037,Disease) :: ['aphasia']


abstract: Side effects of the distal gastrointestinal tract after NSAID use are common and more frequent than previously recognized. Increased @entity33 and @entity32 are often silent but appear after NSAID treatment with most dual COX inhibitors. Other clinical manifestations include: @entity417 , occult @entity190 , @entity8884 , protein-loss, @entity4628 , @entity294 , @entity9645 and strictures due to @entity66 . More common complications are @entity360 and perforation, which represent at least one third of all @entity344 observed with NSAID use. Studies with selective @entity2247 inhibitors have shown that, in the short term, these agents do not increase @entity33 or induce @entity417 due to @entity548 and that, when compared to dual COX inhibitors, lower @entity344 may be reduced by 50%. In order to minimize the impact of these side effects, it is important to increase the current standards of suspicion by physicians who treat these @entity1 , since drug discontinuation may further reduce damage, and clinical experience with agents that may prevent or treat distal tract damage is very limited. From this perspective, selective @entity2247 inhibitors may be the drugs of choice in the high-risk @entity1 that needs NSAIDs. Another important area of uncertainty is the impact of NSAID use in @entity1 with @entity29 . Data from different animal models of @entity29 suggest that inhibition of both @entity9859 and @entity2247 derived prostaglandins affects the severity of the @entity32 . However, current epidemiological and clinical data are contradictory. Since many @entity1 .

title: Clinical implications of XXXX and/or @entity2247 inhibition for the distal gastrointestinal tract.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['mucosal inflammation']

entities_list: @entity8884 :: ('MESH:D008286', 'Disease') :: ['malabsorption']

entities_list: @entity4628 :: ('MESH:D007077', 'Disease') :: ['ileal dysfunction']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity9645 :: ('MESH:D019226', 'Disease') :: ['mucosal ulceration']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucosal permeability']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['diaphragm disease']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal complications']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['occult bleeding']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'inflammatory bowel diseases']

entities_list: @entity360 :: ('MESH:D006471', 'Disease') :: ['lower gastrointestinal bleeding']

answer: @entity9859 :: (4512,Gene) :: ['COX-1']


abstract: OBJECTIVES: To establish the cut-off values for inactive disease, as well as low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA) in @entity262 JIA based on the @entity625 Activity Score (JADAS) and assessed with the 10-joint JADAS (JADAS10) and clinical JADAS10 (cJADAS10). METHODS: In a multicentre cross-sectional study consisting of    20% of all @entity1 with JIA in Finland (n = 509), we obtained data on their most recent registered visits between January 2013 and January 2014. We calculated the JADAS10 and cJADAS10 and established the cut-off values of both of these scores using two different receiver operating characteristics-based statistical methods. RESULTS: Of the 509 @entity1 studied, 65.8% were females and 53.8% had @entity66 . The most suitable method for determining cut-off values was the Youden index. In oligoarticular @entity1 , a JADAS10 score of 0-0.5 represented inactive disease, 0.6-2.7 LDA and >= 2.8 MDA. In @entity66 , a JADAS10 score of 0-0.7 represented inactive disease, 0.8-3.9 LDA and >= 4.0 MDA. The cut-off values for HDA were not possible to establish because only two visits fulfilled HDA criteria. CONCLUSION: We established cut-off values for LDA and MDA. A reliable definition for HDA will require more @entity1 . In the clinical setting, both the cJADAS10 and JADAS10 serve equally well both for research and quality control purposes. In the future, uniform clinical disease activity levels should be established. We also suggest revising and validating the criteria for HDA. Valid and robust cut-off values for disease activity levels can guide both clinicians and researchers and equip them for quality control.

title: Finding specific 10-joint @entity625 Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in @entity262 juvenile idiopathic XXXX : a Finnish multicentre study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity262 :: ('MESH:D034721', 'Disease') :: ['non-systemic']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['Juvenile Arthritis Disease']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['polyarticular disease']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: Latent transforming growth factor (TGF)-beta-binding protein (LTBP) is required for the assembly, secretion, matrix association, and activation of latent TGF-beta complex. To elucidate the cell specific expression of the genes of @entity2535 and their splice variants and the factors that regulate the gene expression, we cultured primary @entity1 glomerular endothelial cells (HGEC) under different conditions. Basal expression of @entity2535 mRNA was suppressed in HGEC compared to WI-38 @entity1 embryonic lung fibroblasts. High @entity413 , @entity274 , and @entity2535 upregulated and @entity7 ( @entity7 ) further downregulated @entity2535 mRNA in HGEC. RT-PCR with a primer set for LTBP-1S produced many clones but no clone was gained with a primer set for LTBP-1L. Of 12 clones selected randomly, Sca I mapping and DNA sequencing revealed that only one was LTBP-1S and all the others were LTBP-1Sdelta53. @entity2535 , but not high @entity413 , @entity274 or @entity7 , tended to increase LTBP-1Sdelta53 mRNA. In conclusion, HGEC express @entity2535 mRNA which is suppressed at basal state but upregulated by high @entity413 , @entity274 , and @entity2535 and downregulated by @entity7 . Major splice variant of @entity2535 in HGEC was LTBP-1S 53. Modification of LTBP-1S 53 gene in HGEC may abrogate fibrotic action of @entity2535 but this requires confirmation.

title: Expression and regulation of latent TGF-beta binding protein-1 transcripts and their splice variants in XXXX glomerular endothelial cells.

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The anther (tapetum)-specific gene BcA9 was isolated from Chinese cabbage, @entity21147 . ssp. pekinensis cv. Jangwon, using the @entity958 tapetum-specific A9 gene as a probe. The DNA and @entity535 sequences of the coding region of the BcA9 gene showed high homology with A9 genes from @entity958 and @entity4335 . However, the DNA sequences of the 5' noncoding (promoter) region were different, except for the sequence from -281 to -89. To test the specific activity of this promoter, a plant expression vector, pGR011, was constructed by fusing the BcA9 promoter and the cytotoxic diphtheria toxin A-chain (DTx-A) gene. Several transgenic plants from cabbage, @entity5598 ssp. capitata, were obtained by way of Agrobacterium-mediated transformation. Southern blot analysis indicated that the tapetum-specific BcA9 promoter and DTx-A gene were successfully integrated into the genome of the transgenic cabbage. Under the control of the BcA9 promoter, expression of the cytotoxic DTx-A gene in the tapetal cells of the transgenic plants resulted in male sterile cabbages. Microscopic examination revealed that pollen grains in anthers of the male sterile cabbages had not developed normally, but the vegetative growth and phenotype showed no difference compared to wild-type plants.

title: Induction of male sterile cabbage using a tapetum-specific promoter from XXXX . ssp. pekinensis.

entities_list: @entity21147 :: ('439823', 'Species') :: ['Brassica campestris L']

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

answer: @entity21147 :: (439823,Species) :: ['Brassica campestris L']


abstract: AIMS: This study aimed to: (1) evaluate cognitive function among adults with @entity3458 using a computer-administered neuropsychological test; and (2) replicate previously identified differences in processing speed between @entity1 with @entity3458 and controls. BACKGROUND: Previous evidence suggests that, compared with controls, adult @entity1 with @entity3458 have poorer cognitive functioning across most domains but the most significant deficits appear to be in the area of processing speed. DESIGN: Cross-sectional case-control study conducted from June 2008-June 2010. METHODS: Cognitive functioning was measured using computerized, self-administered, neuropsychological tests among 31 @entity1 with @entity3458 and 17 controls matched for age, gender and race. The assessment averaged 30  minutes and scores were recorded for seven computerized tests: verbal and visual memory, finger tapping, symbol digit coding, Stroop test, shifting attention and continuous performance. RESULTS: @entity1 with @entity3458 scored 10  76 points lower on the CNS Vital Signs processing speed domain than controls. Although non-significant, @entity1 scored 5  73 points lower on the full index than controls but after adjusting for processing speed, mean scores for @entity1 were 3 points greater compared with controls. Differences in executive functioning and attention were not significant and memory did not differ between groups. CONCLUSION: Using a brief, computer-administered 30-minute neuropsychological test, we were able to replicate previous findings showing a greater than 10-point deficit in processing speed among @entity1 with @entity3458 . When differences in processing speed are taken into account, @entity1 perform equally well or better than controls on cognitive tasks.

title: Adults with XXXX may perform cognitive tests as well as controls when processing speed is taken into account: a preliminary case-control study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['sickle cell disease']

answer: @entity3458 :: (MESH:D000755,Disease) :: ['sickle cell disease']